Experience with everolimusAUGUSTINE, J. J; HRICIK, D. E.Transplantation proceedings. 2004, Vol 36, Num 2S, pp 500S-503S, issn 0041-1345, SUPArticle

Clinical experience with everolimus (certican) : A summaryPONTICELLI, Claudio.Transplantation. 2005, Vol 79, Num 9, pp S93-S94, issn 0041-1337, SUPArticle

Hiperplasia gingival secundaria a everolimus = Gingival Hyperplasia Secondary to Everolimus TherapyPEREZ-BARRIO, S; GONZALEZ HERMOSA, M. R; DIAZ-PEREZ, J. L et al.Actas dermo-sifiliográficas (Ed. impresa). 2010, Vol 101, Num 4, pp 372-373, issn 0001-7310, 2 p.Article

Everolimus. CommentariesCHAPMAN, Therese M; PERRY, Caroline M; VESTER, Udo et al.Drugs (Basel). 2004, Vol 64, Num 8, pp 861-874, issn 0012-6667, 14 p.Article

EverolimusHOUGHTON, Peter J.Clinical cancer research (Print). 2010, Vol 16, Num 5, pp 1368-1372, issn 1078-0432, 5 p.Article

The evolving experience using everolimus in clinical transplantationFORMICA, R. N; LORBER, K. M; FRIEDMAN, A. L et al.Transplantation proceedings. 2004, Vol 36, Num 2S, pp 495S-499S, issn 0041-1345, SUPArticle

Post-transplant proteinuria associated with everolimus : Definition of main features with proteomicsGHIGGERI, Gian Marco; BRUSCHI, Maurizio; ROSAT, Alberto et al.Proteomics. Clinical applications (Print). 2008, Vol 2, Num 9, pp 1327-1337, issn 1862-8346, 11 p.Article

6-Month Clinical Outcomes Following Implantation of the Bioresorbable Everolimus-Eluting Vascular Scaffold in Vessels Smaller or Larger Than 2.5 mmDILETTI, Roberto; ONUMA, Yoshinobu; CHEVALIER, Bernard et al.Journal of the American College of Cardiology. 2011, Vol 58, Num 3, pp 258-264, issn 0735-1097, 7 p.Article

Preclinical evidences suggest new treatment options for endocrine disorders : Pasireotide (SOM230) and Everolimus (RAD001)SCHMID, H. A.Annales d'endocrinologie. 2008, Vol 69, Num 2, pp 162-163, issn 0003-4266, 2 p.Conference Paper

Clinical experience with everolimus (certican) in elderly recipients : The old-for-old conceptPASCUAL, Julio; MARCEN, Roberto; ORTUNO, Joaquin et al.Transplantation. 2005, Vol 79, Num 9, pp S85-S88, issn 0041-1337, SUPArticle

Les inhibiteurs de la mTOR et le FTY 720 = Inhibitors of mammalian target of rapamycin (mTOR)SOLIGNAC, Marie; MOREL, D.La Presse médicale (1983). 2001, Vol 30, Num 24, pp 35-37, issn 0755-4982, 2Conference Paper

Everolimus alters white matter diffusion in tuberous sclerosis complexTILLEMA, Jan-Mendelt; LEACH, James L; KRUEGER, Darry A et al.Neurology. 2012, Vol 78, Num 8, pp 526-531, issn 0028-3878, 6 p.Article

Dedicated everolimus-eluting side branch access system: XIENCE SBASOROP, Oana; HATTEN, Thomas R; VAN BEUSEKOM, Heleen M. M et al.EuroIntervention. 2010, Vol 6, issn 1774-024X, J155-J160, SUPJArticle

Introducing everolimus (certican) in organ transplantation : An overview of preclinical and early clinical developmentsNEUMAYER, Hans-Hellmut.Transplantation. 2005, Vol 79, Num 9, pp S72-S75, issn 0041-1337, SUPArticle

Concentration-controlled everolimus (certican) : Combination with reduced dose calcineurin inhibitorsPASCUAL, Julio.Transplantation. 2005, Vol 79, Num 9, pp S76-S79, issn 0041-1337, SUPArticle

Everolimus in pediatric de novo renal transplant patientsHOYER, Peter F; ETTENGER, Robert; OFFNER, Gisela et al.Transplantation. 2003, Vol 75, Num 12, pp 2082-2085, issn 0041-1337, 4 p.Article

Clinical experience with everolimus (certican) in young renal transplant recipientsERIS, Josette.Transplantation. 2005, Vol 79, Num 9, pp S89-S92, issn 0041-1337, SUPArticle

Clinical and intravascular imaging outcomes at 1 and 2 years after implantation of absorb everolimus eluting bioresorbable vascular scaffolds in small vessels. Late lumen enlargement: does bioresorption matter with small vessel size? Insight from the ABSORB cohort B trialDILETTI, Roberto; FAROOQ, Vasim; DUDEK, Dariusz et al.Heart (London 1996). 2013, Vol 99, Num 2, pp 98-105, issn 1355-6037, 8 p.Article

Corneal Permeation Studies of Everolimus MicroemulsionBASPINAR, Yuecel; BERTELMANN, Eckart; PLEYER, Uwe et al.Journal of ocular pharmacology and therapeutics. 2008, Vol 24, Num 4, pp 399-402, issn 1080-7683, 4 p.Article

Clinical pharmacokinetics of everolimusKIRCHNER, Gabriele I; MEIER-WIEDENBACH, Ivo; MANNS, Michael P et al.Clinical pharmacokinetics. 2004, Vol 43, Num 2, pp 83-95, issn 0312-5963, 13 p.Article

The Macrolide Everolimus Forms an Unusual Metabolite in Animals and Humans : Identification of a Phosphocholine EsterZOLLINGER, Markus; SAYER, Claudia; DANNECKER, Robert et al.Drug metabolism and disposition. 2008, Vol 36, Num 8, pp 1457-1460, issn 0090-9556, 4 p.Article

Everolimus eluting stents : beyond targeting restenosis!FLAN, Aloke V; NAKAZAWA, Gaku; JONER, Michael et al.EuroIntervention. 2006, Vol 2, Num 3, pp 277-279, issn 1774-024X, 3 p.Article

Six- and twelve-month results from First human experience using everolimus-eluting stents with bioabsorbable polymerGRUBE, Eberhard; SONODA, Shinjo; IKENO, Fumiaki et al.Circulation (New York, N.Y.). 2004, Vol 109, Num 18, pp 2168-2171, issn 0009-7322, 4 p.Article

Évérolimus (Certican®, Novartis) en transplantation rénale : Dossier transplantation et suivi thérapeutique pharmacologique = Everolimus (Certican®, Novartis) in renal transplantationDANTAL, Jacques.La Lettre du pharmacologue (Boulogne). 2008, Vol 22, Num 1, pp 21-24, issn 0984-452X, 4 p.Article

Rash to the mTOR Inhibitor Everolimus Systematic Review and Meta-AnalysisRAMIREZ-FORT, Marigdalia K; CASE, Emily C; ROSEN, Alyx C et al.American journal of clinical oncology. 2014, Vol 37, Num 3, pp 266-271, issn 0277-3732, 6 p.Article